{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:01:40Z","timestamp":1791928900326,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejca.2023.02.019","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T19:28:28Z","timestamp":1677266908000},"page":"94-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"special_numbering":"C","title":["Anthracycline-induced cardiotoxicity \u2014 are we about to clear this hurdle?"],"prefix":"10.1016","volume":"185","author":[{"given":"Wolfram C.M.","family":"Dempke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Silberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Reuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Priebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.02.019_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cts.12857","article-title":"Epigenetic changes associated with anthracycline-induced cardiotoxicity","volume":"14","author":"Tantawy","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ejca.2023.02.019_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12944-022-01694-y","article-title":"Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?","volume":"21","author":"Abrahams","year":"2022","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ejca.2023.02.019_bib3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejca.2005.11.003","article-title":"Caring for survivor of childhood cancers: the size of the problem","volume":"42","author":"Curry","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.ejca.2023.02.019_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0167-4781(92)90050-A","article-title":"Different patterns of gene expression to topoisomerase II isoforms in differentiated tissues during murine development","volume":"1132","author":"Capranico","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2023.02.019_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejca.2023.02.019_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.00035","article-title":"Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer?","volume":"7","author":"Murabito","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejca.2023.02.019_bib9","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejca.2023.02.019_bib10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system \u2013 from molecular mechanisms to therapeutic applications","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejca.2023.02.019_bib11","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.02.019_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11897-020-00489-5","article-title":"Anthracycline-related heart failure: certain knowledge and open questions","volume":"17","author":"Robinson","year":"2020","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.ejca.2023.02.019_bib13","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejca.2023.02.019_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejca.2023.02.019_bib15","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/14779072.2016.1239528","article-title":"Chemotherapy-induced cardiotoxicity: importance of early detection","volume":"14","author":"Cardinale","year":"2016","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ejca.2023.02.019_bib16","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejca.2023.02.019_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MPH.0000000000001118","article-title":"Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumors \u2013 a systematic review","volume":"40","author":"Liesse","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7326\/0003-4819-88-2-168","article-title":"Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catherization","volume":"88","author":"Bristow","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2023.02.019_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54669","article-title":"Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010","volume":"6","author":"Larsen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2023.02.019_bib20","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Associatin (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejca.2023.02.019_bib21","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s11010-021-04152-y","article-title":"Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in woman with breast cancer","volume":"476","author":"Varghese","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.ejca.2023.02.019_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","article-title":"Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention","volume":"1257","author":"Bhagat","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ejca.2023.02.019_bib23","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"Celutkien\u00e9","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejca.2023.02.019_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in caner patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejca.2023.02.019_bib25","first-page":"34","article-title":"The prognosis of cancer patients undergoing liposomal doxorubicin-based chemotherapy","volume":"100","author":"Zhang","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.ejca.2023.02.019_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","article-title":"Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Ovarian Res"},{"issue":"suppl","key":"10.1016\/j.ejca.2023.02.019_bib27","article-title":"Phase III study of aldoxorubicin vs investigators\u2019 choice as treatment for relapsed\/refractory soft tissue sarcomas","volume":"35","author":"Chawla","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","volume":"17","author":"Van Glabbeke","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib29","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2147\/OTT.S145539","article-title":"Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date","volume":"12","author":"Cranmer","year":"2019","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ejca.2023.02.019_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.22409","article-title":"The 6-maleimidocaproyl-hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage","volume":"120","author":"Lebrecht","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0960327107073825","article-title":"Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrozone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin","volume":"26","author":"Kratz","year":"2007","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.ejca.2023.02.019_bib32","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jamaoncol.2015.3101","article-title":"First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2a randomized clinical trial","volume":"1","author":"Chawla","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib33","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.ejca.2005.10.030","article-title":"Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin","volume":"42","author":"Dubois","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib34","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-07-1165","article-title":"Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptide prodrug of doxorubicin","volume":"14","author":"Ravel","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.02.019_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejca.2017.09.009","article-title":"First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced metastatic solid tumours","volume":"86","author":"Sch\u00f6ffski","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10637-016-0388-x","article-title":"Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase II\u03b2 activity and cardiac function in a chronic rabbit model","volume":"34","author":"Frank","year":"2016","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.ejca.2023.02.019_bib37","unstructured":"\u3008https:\/\/www.monopartx.com\/pipeline\/Camsirubicin\/clinical-data\u3009 (assessed November 20, 2022)."},{"key":"10.1016\/j.ejca.2023.02.019_bib38","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/cam4.2136","article-title":"A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastastic and unresectable soft tissue sarcoma","volume":"8","author":"Van Tine","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2023.02.019_bib39","unstructured":"VS Chua S Chawla E Gordon et al. Phase1b trial of camsirubicin, a novel doxorubicin analog, with concomitantpegfilgrastim for advanced soft tissue sarcoma to identify a new maximumtolerated dose\/recommended phase 2 dose. https:\/\/www.eventscribe.net\/2022\/CTOS\/fsPopup.asp?efp=QUpSRUVSU1AxNzQ5Ng&PosterID=525853&rnd=0.6952818&mode=posterinfo."},{"key":"10.1016\/j.ejca.2023.02.019_bib40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Annal Oncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","article-title":"Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer","volume":"15","author":"LiX-R","year":"2022","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ejca.2023.02.019_bib42","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1021\/acsomega.7b01235","article-title":"Cardinal role of intraliposome doxorubicin-sulfate nanorod crystal in Doxil properties and performance","volume":"3","author":"Wei","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejca.2023.02.019_bib43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/CAD.0000000000000521","article-title":"Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg\/m\u00b2 in recurrent ovarian cancer","volume":"28","author":"Pendleburg","year":"2017","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2023.02.019_bib44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/aogs.12642","article-title":"Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study","volume":"94","author":"Rabinovich","year":"2015","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ejca.2023.02.019_bib45","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ygyno.2013.03.012","article-title":"Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?","volume":"129","author":"Gill","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clbc.2013.10.011","article-title":"Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer","volume":"14","author":"Misra","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib47","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC soft tissue and bone sarcoma group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib48","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.ejca.2009.08.016","article-title":"Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis","volume":"45","author":"Constantinidou","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs"},{"key":"10.1016\/j.ejca.2023.02.019_bib50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib51","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"Asselin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12885-016-2654-x","article-title":"Efficacy and safety of dexraxozane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy \u2013 a retrospective study including 32 patients","volume":"16","author":"Schuler","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib53","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas","volume":"323","author":"Tap","year":"2002","journal-title":"JAMA"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2023.02.019_bib54","article-title":"Assessment of cardiotoxicity (CT) associated with doxorubicin (dox) in patients (pts) with advanced soft tissue sarcomas (STS) in a phase III randomized trial","volume":"30","author":"Jones","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.02.019_bib56","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1186\/s12885-020-07663-x","article-title":"High cumulative doxorubicin dose for advanced soft tissue sarcoma","volume":"20","author":"Tian","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.02.019_bib57","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1535-7163.1403.3.11","article-title":"Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues","volume":"3","author":"Trevino","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2023.02.019_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00001813-199302000-00005","article-title":"Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity","volume":"4","author":"Priebe","year":"1993","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ejca.2023.02.019_bib59","author":"Zielinski"},{"key":"10.1016\/j.ejca.2023.02.019_bib60","first-page":"1369","article-title":"Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity","volume":"1","author":"Zou","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.02.019_bib61","unstructured":"\u3008www.moleculin.com\u3009 (assessed February 10, 2023)."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:58Z","timestamp":1760733598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":61,"alternative-id":["S0959804923001132"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anthracycline-induced cardiotoxicity \u2014 are we about to clear this hurdle?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}